{"id":742279,"date":"2013-11-26T09:00:00","date_gmt":"2013-11-26T09:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/"},"modified":"2023-03-22T00:04:31","modified_gmt":"2023-03-22T04:04:31","slug":"fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/","title":{"rendered":"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      approved NOXAFIL<sup>\u00ae<\/sup> (posaconazole) 100 mg delayed-release<br \/>\n      tablets. NOXAFIL delayed-release tablets are a new formulation with a<br \/>\n      loading dose of 300 mg (three 100 mg delayed-release tablets) twice<br \/>\n      daily on the first day, followed by a once-daily maintenance dose of 300<br \/>\n      mg (three 100 mg delayed-release tablets) starting on the second day of<br \/>\n      therapy. Merck also markets NOXAFIL (40 mg\/mL) oral suspension, which is<br \/>\n      dosed three times daily.\n    <\/p>\n<p>\n      NOXAFIL delayed-release tablets and oral suspension are indicated for<br \/>\n      the prophylaxis of invasive <i>Aspergillus<\/i> and <i>Candida<\/i><br \/>\n      infections in patients, 13 years of age and older, who are at high risk<br \/>\n      of developing these infections due to being severely immunocompromised,<br \/>\n      such as hematopoietic stem cell transplant (HSCT) recipients with<br \/>\n      graft-versus-host disease (GVHD) or those with hematologic malignancies<br \/>\n      with prolonged neutropenia (low white blood cell counts) from<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      NOXAFIL should not be administered to persons allergic to posaconazole,<br \/>\n      any ingredients of NOXAFIL, or other azole antifungal medicines. The<br \/>\n      administration of NOXAFIL with sirolimus, pimozide, quinidine,<i> <\/i>atorvastatin,<br \/>\n      lovastatin, simvastatin and ergot alkaloids must be avoided. When<br \/>\n      administered with NOXAFIL, some drugs such as cyclosporine and<br \/>\n      tacrolimus required dosage adjustments and frequent monitoring of their<br \/>\n      levels in the blood as serious side effects of the kidney<br \/>\n      (nephrotoxicity) or brain (leukoencephalopathy) including deaths have<br \/>\n      been reported in patients with increased cyclosporine or tacrolimus<br \/>\n      blood levels. NOXAFIL should be administered with caution to patients<br \/>\n      who may develop an irregular heart rhythm as NOXAFIL has been shown to<br \/>\n      prolong the QT interval and cases of potentially fatal irregular heart<br \/>\n      rhythm (torsades de pointes) have been reported in patients taking<br \/>\n      NOXAFIL. (See Selected Safety Information below.)\n    <\/p>\n<p>\n      \u201cProphylaxis against invasive <i>Aspergillus <\/i>and <i>Candida <\/i>infections<br \/>\n      plays a key role in the management of severely immunocompromised<br \/>\n      patients with hematologic malignancies or hematopoietic stem cell<br \/>\n      transplant recipients who are at high risk for these life-threatening<br \/>\n      fungal infections,&#8221; said Daniel Couriel, M.D., professor of internal<br \/>\n      medicine and clinical program director, adult blood and marrow<br \/>\n      transplantation program, University of Michigan Comprehensive Cancer<br \/>\n      Center. \u201cPosaconazole delayed-release tablets offer physicians a way to<br \/>\n      help protect these critically ill patients against invasive <i>Aspergillus<br \/>\n      <\/i>and <i>Candida <\/i>infections while they are in the hospital and<br \/>\n      once they return home.\u201d\n    <\/p>\n<p>\n      <b>FDA approval of NOXAFIL (posaconazole) delayed-release tablets based<br \/>\n      on a pharmacokinetic study in patients<\/b>\n    <\/p>\n<p>\n      A non-comparative, multicenter study was performed to evaluate the<br \/>\n      pharmacokinetic properties, safety and tolerability of NOXAFIL<br \/>\n      delayed-release tablets in patients with acute myeloid leukemia (AML) or<br \/>\n      myelodysplastic syndrome (MDS) who had developed or were anticipated to<br \/>\n      develop significant neutropenia, and in patients who had undergone HSCT<br \/>\n      and were receiving immunosuppressive therapy for prevention or treatment<br \/>\n      of GVHD. In the study, exposures of posaconazole within a pre-specified<br \/>\n      range were attained. The exposure levels achieved support a 300 mg<br \/>\n      (three 100 mg delayed-release tablets) once-daily dose of NOXAFIL<br \/>\n      delayed-release tablets, following a 300 mg (three 100 mg<br \/>\n      delayed-release tablets) twice-a-day loading dose on the first day of<br \/>\n      therapy. The most frequently reported adverse reactions (>25%) with<br \/>\n      NOXAFIL delayed-release tablets were diarrhea, fever and nausea. The<br \/>\n      type of adverse reactions reported for NOXAFIL delayed-release tablets<br \/>\n      were generally similar to that reported in trials of NOXAFIL oral<br \/>\n      suspension. (See Selected Safety Information below.)\n    <\/p>\n<p>\n      The effect of food intake on the oral bioavailability of posaconazole<br \/>\n      following administration of NOXAFIL delayed-release tablets is not<br \/>\n      known. However, since the oral bioavailability of posaconazole is<br \/>\n      significantly increased when NOXAFIL oral suspension is administered<br \/>\n      with food or a nutritional supplement, or an acidic carbonated beverage<br \/>\n      (e.g., ginger ale) in patients who cannot eat a full meal, it is also<br \/>\n      recommended that NOXAFIL delayed-release tablets be taken with food. For<br \/>\n      patients who cannot eat a full meal, NOXAFIL delayed-release tablets<br \/>\n      should be used instead of NOXAFIL oral suspension for the prophylaxis<br \/>\n      indication. NOXAFIL delayed-release tablets provide higher plasma drug<br \/>\n      exposures than NOXAFIL oral suspension under fasted conditions.\n    <\/p>\n<p>\n      NOXAFIL delayed-release tablets should be swallowed whole, and not be<br \/>\n      divided, crushed or chewed. Coadministration of drugs that can decrease<br \/>\n      the plasma concentrations of posaconazole should generally be avoided<br \/>\n      unless the benefit outweighs the risk. If such drugs are necessary,<br \/>\n      patients should be monitored closely for breakthrough fungal infections.<br \/>\n      Patients who have severe diarrhea or vomiting should be monitored<br \/>\n      closely for breakthrough fungal infections.\n    <\/p>\n<p>\n      <b>Clinical experience with NOXAFIL (posaconazole) oral suspension for<br \/>\n      antifungal prophylaxis<\/b>\n    <\/p>\n<p>\n      Two clinical studies of prophylaxis against invasive fungal infections<br \/>\n      were conducted with NOXAFIL oral suspension. Both studies demonstrated<br \/>\n      substantially fewer breakthrough infections caused by <i>Aspergillus<\/i><br \/>\n      species in patients receiving posaconazole prophylaxis when compared to<br \/>\n      patients receiving fluconazole or itraconazole.\n    <\/p>\n<p>\n      In one randomized, open-label study that compared posaconazole oral<br \/>\n      suspension (200 mg three times a day) with fluconazole suspension (400<br \/>\n      mg once daily) or itraconazole oral solution (200 mg twice daily) as<br \/>\n      prophylaxis against invasive fungal infections in neutropenic patients<br \/>\n      receiving cytotoxic chemotherapy for AML or MDS (n=602), clinical<br \/>\n      failure in patients while receiving antifungal prophylaxis and for seven<br \/>\n      days following the last dose of therapy was lower for posaconazole (27%<br \/>\n      [82\/304]) compared to fluconazole or itraconazole (42% [126\/298]), (95%<br \/>\n      CI for the difference posaconazole-comparator -22.9% to -7.8%). Clinical<br \/>\n      failure at 100 days post-randomization was 52% (158\/304]) for<br \/>\n      posaconazole compared to 64% (191\/298) for fluconazole or itraconazole.<br \/>\n      All-cause mortality was lower at 100 days for patients receiving<br \/>\n      posaconazole (14% [44\/304]) vs. fluconazole or itraconazole (21%<br \/>\n      [64\/298]).\n    <\/p>\n<p>\n      In a randomized, double-blind study that compared posaconazole oral<br \/>\n      suspension (200 mg three times a day) with fluconazole capsules (400 mg<br \/>\n      once daily) as prophylaxis against invasive fungal infections in<br \/>\n      allogeneic HSCT recipients with GVHD (n=600), the clinical failure rate<br \/>\n      on therapy plus 7 days was 17% (50\/301) for posaconazole and 18%<br \/>\n      (55\/299) for fluconazole. Clinical failure through 16 weeks<br \/>\n      post-randomization was similar for posaconazole (33% [99\/301]) and<br \/>\n      fluconazole (37% [110\/299]), (95% CI for the difference<br \/>\n      posaconazole-comparator -11.5% to 3.7%). All-cause mortality was similar<br \/>\n      at 16 weeks for both treatment arms 19% ([58\/301] vs. 20% [59\/299]),<br \/>\n      respectively.\n    <\/p>\n<p>\n      Clinical failure in these studies represented a composite endpoint of<br \/>\n      breakthrough invasive fungal infections, mortality and use of systemic<br \/>\n      antifungal therapy.\n    <\/p>\n<p>\n      The most frequently reported adverse reactions (>30%) in these<br \/>\n      prophylaxis studies with NOXAFIL oral suspension were fever, diarrhea<br \/>\n      and nausea.\n    <\/p>\n<p>\n      NOXAFIL delayed-release tablets and oral suspension are not to be used<br \/>\n      interchangeably due to the differences in the dosing of each formulation.\n    <\/p>\n<p>\n      <b>Selected Safety Information<\/b>\n    <\/p>\n<p>\n      NOXAFIL (posaconazole) is contraindicated in persons with known<br \/>\n      hypersensitivity to posaconazole, any component of NOXAFIL, or other<br \/>\n      azole antifungal agents.\n    <\/p>\n<p>\n      NOXAFIL is contraindicated with sirolimus. Concomitant administration of<br \/>\n      NOXAFIL with sirolimus increases the sirolimus blood concentrations by<br \/>\n      approximately 9-fold and can result in sirolimus toxicity.\n    <\/p>\n<p>\n      NOXAFIL is contraindicated with CYP3A4 substrates that prolong the QT<br \/>\n      interval. Concomitant administration of NOXAFIL with the CYP3A4<br \/>\n      substrates, pimozide and quinidine may result in increased plasma<br \/>\n      concentrations of these drugs, leading to QT prolongation and cases of<br \/>\n      torsades de pointes.\n    <\/p>\n<p>\n      NOXAFIL is contraindicated with HMG-CoA reductase inhibitors that are<br \/>\n      primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin and<br \/>\n      simvastatin) as increased plasma concentration of these drugs can lead<br \/>\n      to rhabdomyolysis.\n    <\/p>\n<p>\n      NOXAFIL is contraindicated with ergot alkaloids. NOXAFIL may increase<br \/>\n      the plasma concentrations of ergot alkaloids (ergotamine and<br \/>\n      dihydroergotamine) which may lead to ergotism.\n    <\/p>\n<p>\n      Concomitant administration of NOXAFIL with cyclosporine or tacrolimus<br \/>\n      increases the whole blood trough concentrations of these calcineurin<br \/>\n      inhibitors. Nephrotoxicity and leukoencephalopathy (including deaths)<br \/>\n      have been reported in clinical efficacy studies in patients with<br \/>\n      elevated cyclosporine or tacrolimus concentrations. Frequent monitoring<br \/>\n      of cyclosporine or tacrolimus whole blood trough concentrations should<br \/>\n      be performed during and at discontinuation of NOXAFIL treatment and the<br \/>\n      tacrolimus or cyclosporine dose adjusted accordingly.\n    <\/p>\n<p>\n      Some azoles, including NOXAFIL, have been associated with prolongation<br \/>\n      of the QT interval on the electrocardiogram. In addition, cases of<br \/>\n      torsades de pointes have been reported in patients taking NOXAFIL.<br \/>\n      NOXAFIL should be administered with caution to patients with potentially<br \/>\n      proarrhythmic conditions. Do not administer with drugs that are known to<br \/>\n      prolong the QT interval and are metabolized through CYP3A4. Rigorous<br \/>\n      attempts to correct potassium, magnesium and calcium should be made in<br \/>\n      these patients before starting NOXAFIL.\n    <\/p>\n<p>\n      Hepatic reactions (e.g., mild to moderate elevations in ALT, AST,<br \/>\n      alkaline phosphatase, total bilirubin and\/or clinical hepatitis) have<br \/>\n      been reported in clinical trials. The elevations in liver function tests<br \/>\n      were generally reversible on discontinuation of therapy, and in some<br \/>\n      instances these tests normalized without drug interruption. Cases of<br \/>\n      more severe hepatic reactions including cholestasis or hepatic failure<br \/>\n      including deaths have been reported in patients with serious underlying<br \/>\n      medical conditions (e.g., hematologic malignancy) during treatment with<br \/>\n      NOXAFIL. Liver function tests should be evaluated at the start of and<br \/>\n      during the course of therapy. Patients who develop abnormal liver<br \/>\n      function tests during posaconazole therapy should be monitored for the<br \/>\n      development of more severe hepatic injury. Consider discontinuation of<br \/>\n      NOXAFIL (posaconazole) if clinical signs and symptoms consistent with<br \/>\n      liver disease develop that may be attributable to NOXAFIL.\n    <\/p>\n<p>\n      Concomitant administration of NOXAFIL with midazolam increases the<br \/>\n      midazolam plasma concentrations by approximately 5-fold which could<br \/>\n      potentiate and prolong hypnotic and sedative effects. Concomitant use of<br \/>\n      NOXAFIL and other benzodiazepines metabolized by CYP3A4 (e.g.,<br \/>\n      alprazolam, triazolam) could result in increased plasma concentrations<br \/>\n      of theses benzodiazepines. Patients must be monitored closely for<br \/>\n      adverse effects associated with high plasma concentrations of midazolam<br \/>\n      and other benzodiazepines metabolized by CYP3A4. In addition,<br \/>\n      benzodiazepine receptor antagonists must be available to reverse these<br \/>\n      effects.\n    <\/p>\n<p>\n      Posaconazole is primarily metabolized via UDP glucuronidation and is a<br \/>\n      substrate of p-glycoprotein efflux. Therefore, inhibitors or inducers of<br \/>\n      these clearance pathways may affect posaconazole plasma concentrations.<br \/>\n      Coadministration of drugs that can decrease the plasma concentrations of<br \/>\n      posaconazole should generally be avoided unless the benefit outweighs<br \/>\n      the risk. If such drugs are necessary, patients should be monitored<br \/>\n      closely for breakthrough fungal infections. Posaconazole is also a<br \/>\n      strong inhibitor of CYP3A4. Therefore, plasma concentrations of drugs<br \/>\n      predominantly metabolized by CYP3A4 may be increased by posaconazole.\n    <\/p>\n<p>\n      Coadministration of NOXAFIL with rifabutin, phenytoin and efavirenz<br \/>\n      should be avoided unless the benefit outweighs the risk. Monitoring for<br \/>\n      toxicity and\/or adverse events is recommended when tacrolimus,<br \/>\n      cyclosporine, benzodiazepines, ritonavir, atazanavir, vinca alkaloids<br \/>\n      and calcium channel blockers and rifabutin are coadministered with<br \/>\n      NOXAFIL. Dosage adjustments should also be considered when tacrolimus,<br \/>\n      cyclosporine, vinca alkaloids, calcium channel blockers and phenytoin<br \/>\n      are administered with NOXAFIL. Monitor plasma concentrations when<br \/>\n      coadministering digoxin, phenytoin, tacrolimus and cyclosporine with<br \/>\n      NOXAFIL. Although no dosage adjustment of glipizide is required, it is<br \/>\n      recommended to monitor glucose concentrations when coadministering<br \/>\n      glipizide with NOXAFIL. Monitor for breakthrough fungal infections when<br \/>\n      coadministering fosamprenavir, rifabutin and phenytoin with NOXAFIL.\n    <\/p>\n<p>\n      Coadministration of NOXAFIL oral suspension with cimetidine (an H<sub>2<\/sub>-receptor<br \/>\n      antagonist) and esomeprazole (a proton pump inhibitor) results in lower<br \/>\n      posaconazole plasma concentrations and should be avoided unless the<br \/>\n      benefit outweighs the risk. No clinically relevant effects were observed<br \/>\n      when posaconazole oral suspension is concomitantly used with antacids<br \/>\n      and H<sub>2<\/sub>-receptor antagonists other than cimetidine.\n    <\/p>\n<p>\n      Coadministration of NOXAFIL oral suspension with metoclopramide<br \/>\n      decreases posaconazole plasma concentrations; however loperamide does<br \/>\n      not affect posaconazole plasma concentrations.<sup> <\/sup>Monitor for<br \/>\n      breakthrough fungal infections when coadministering cimetidine,<br \/>\n      esomeprazole and metoclopramide with NOXAFIL (posaconazole) oral<br \/>\n      suspension.\n    <\/p>\n<p>\n      No clinically relevant effects on the pharmacokinetics of posaconazole<br \/>\n      delayed-release tablets were observed when concomitantly administered<br \/>\n      with drugs affecting gastric pH (i.e., antacids, H<sub>2<\/sub>-receptor<br \/>\n      antagonists, proton pump inhibitors). Concomitant administration of<br \/>\n      metoclopramide with posaconazole delayed-release tablets did not affect<br \/>\n      the pharmacokinetics of posaconazole.\n    <\/p>\n<p>\n      The safety and effectiveness of NOXAFIL in patients below the age of 13<br \/>\n      years old have not been established.\n    <\/p>\n<p>\n      Patients weighing greater than 120 kg may have lower posaconazole plasma<br \/>\n      drug exposures. It is therefore, suggested to closely monitor for<br \/>\n      breakthrough fungal infections.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=12fd8bb63d085f9b56b19bbc475f7137\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.twitter%2FMerck&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=98490e91a42dbc966d2c66fcc8b1c3e1\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=250a9b4bd7df58183de32e39faa3c94b\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=fccc4c646ae1a50baebcd6fb1d9d1a07\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=efbacb6e36a9b6a5b32388593c4078c4\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for NOXAFIL (posaconazole)<br \/>\n      delayed-release tablets and oral suspension at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.spfiles.com%2Fpinoxafil.pdf&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.spfiles.com%2Fpinoxafil.pdf&#038;index=6&#038;md5=e9532d7eece89efa94d2cb09e97a7a15\" rel=\"nofollow\"><b>http:\/\/www.spfiles.com\/pinoxafil.pdf<\/b><\/a><b><br \/>\n      and Patient Information for NOXAFIL at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.spfiles.com%2Fppinoxafil.pdf&#038;esheet=50758401&#038;newsitemid=20131126005654&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.spfiles.com%2Fppinoxafil.pdf&#038;index=7&#038;md5=a1cf9816e11a1d4803ed1367d4847927\" rel=\"nofollow\"><b>http:\/\/www.spfiles.com\/ppinoxafil.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>NOXAFIL<\/b><sup><b>\u00ae <\/b><\/sup><b>is a registered trademark of Merck<br \/>\n      Sharp &#038; Dohme Corp., a subsidiary of Merck &#038; Co., Inc., Whitehouse<br \/>\n      Station, N.J., USA.<\/b>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20131126005654r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pam Eisele, 908-423-5042<br \/>Robert        Consalvo, 908-423-6595<br \/>or<br \/>Investor Contacts:<br \/>Carol        Ferguson, 908-423-4465<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL \u00ae (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Merck also markets NOXAFIL (40 mg\/mL) oral suspension, which is dosed three times daily. NOXAFIL delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-742279","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL \u00ae (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Merck also markets NOXAFIL (40 mg\/mL) oral suspension, which is dosed three times daily. NOXAFIL delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/\",\"name\":\"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2013-11-26T09:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL \u00ae (posaconazole) 100 mg delayed-release tablets. NOXAFIL delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets) starting on the second day of therapy. Merck also markets NOXAFIL (40 mg\/mL) oral suspension, which is dosed three times daily. NOXAFIL delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:31+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/","name":"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx","datePublished":"2013-11-26T09:00:00+00:00","dateModified":"2023-03-22T04:04:31+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20131126005654r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fda-approves-mercks-noxafil-posaconazole-delayed-release-tablets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"FDA Approves Merck\u2019s NOXAFIL\u00ae (posaconazole) Delayed-Release Tablets"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0604e230-6e2d-494c-a5ca-82e65f137a0a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742279\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742279"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}